<p>Cybin Inc.（纽约美国交易所：CYBN）在 6 月份的空头头寸显著减少。截至 6 月 15 日，空头头寸总计为 20,550,000 股，较 5 月 31 日的 22,990,000 股减少了 10.6%。根据平均交易量为 4,040,000 股，目前的偿付天数比率为 5.1 天。目前，该股的 3.0% 股份被做空。</p>
<h2>机构投资者对 Cybin 的看法</h2>
<p>机构投资者和对冲基金最近对该公司的持股进行了调整。Rathbones Group PLC 在第四季度购入了 Cybin 股票，价值约 26,000 美元。 Cerity Partners LLC 在第四季度将其对 Cybin 的持股增加了 488.5%。 Cerity Partners LLC 现在拥有公司股票的 88,271 股，价值 36,000 美元，比上一季度增加了 73,271 股。 Thrive Wealth Management LLC 在第四季度将其对 Cybin 的持股增加了 141.5%。 Thrive Wealth Management LLC 现在拥有公司股票的 128,000 股，价值 52,000 美元，比上一季度增加了 75,000 股。 Lewis Asset Management LLC 在第四季度购入了 Cybin 的新头寸，价值约 116,000 美元。最后，FNY Investment Advisers LLC 在第四季度将其对 Cybin 的持股增加了 20,000.0%。 FNY Investment Advisers LLC 现在拥有公司股票的 402,000 股，价值 164,000 美元，比上一季度增加了 400,000 股。目前，17.94% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>Cybin 股票表现</h2>
<p>Cybin 股票周三开盘价为 0.26 美元。 Cybin 股票 52 周最低价为 0.25 美元，52 周最高价为 0.74 美元。该股的市值为 1.0884 亿美元，市盈率为-1.26，β系数为 0.50。</p>
<h2>华尔街分析师的观点</h2>
<p>HC Wainwright 重申对 Cybin 的 “买入” 评级，并在 3 月 13 日的研究报告中给出了 5.00 美元的目标价。</p>
<p><strong>查看我们关于 CYBN 的最新报告</strong></p>
<h2>Cybin 公司简介（获取免费报告）</h2>
<p>Cybin Inc 是一家临床阶段的生物制药公司，专注于开发基于致幻物质的治疗药物。该公司的开发管线包括 CYB003，一种氘代哌苷类似物，目前正在进行治疗重度抑郁症和酒精成瘾的 1/2a 期临床试验；CYB004，一种氘代二甲基色胺，目前正在进行治疗广泛性焦虑症的 1 期临床试验；以及 CYB005，一种苯乙胺衍生物，目前处于临床前阶段，用于治疗神经炎症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票胜过 Cybin</li>
<li>什么是特别股息？</li>
<li>Generac Holdings 股票：混合信号让投资者感到不确定</li>
<li>投资的股票类型有所不同</li>
<li>分析师和盈利推动标普 500 持续增长</li>
<li>波动时期必须购买的三只沃伦·巴菲特股票</li>
<li>CrowdStrike 股票飙升，超越 Palo Alto 在网络安全领域</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 您唯一需要的退休股票？立即发现（来自市场背后的信息）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjM2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjM2"/></p>
<h2>您现在是否应该投资 1,000 美元购买 Cybin 股票？</h2>
<p>在考虑 Cybin 之前，您需要听到这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶尖分析师悄悄告诉客户现在购买的股票...而 Cybin 不在名单上。</p>
<p>尽管 Cybin 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CYBN

HELP

<p>Cybin Inc.（NYSEAMERICAN:CYBN）在六月份经历了空头头寸的显著下降，与五月相比下降了 10.6%。该公司的股票目前的空头比率为 3.0%。此外，机构投资者和对冲基金已经调整了他们在 Cybin 的持仓。该股周三开盘价为$0.26，市值为$108.84 百万美元</p>

<p>Cybin Inc. (NYSEAMERICAN:CYBN - Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 20,550,000 shares, a decrease of 10.6% from the May 31st total of 22,990,000 shares. Based on an average trading volume of 4,040,000 shares, the days-to-cover ratio is presently 5.1 days. Currently, 3.0% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>Cybin Inc.（纽约美国交易所：CYBN）在 6 月份的空头头寸显著减少。截至 6 月 15 日，空头头寸总计为 20,550,000 股，较 5 月 31 日的 22,990,000 股减少了 10.6%。根据平均交易量为 4,040,000 股，目前的偿付天数比率为 5.1 天。目前，该股的 3.0% 股份被做空。</p>
</div><h2>Institutional Investors Weigh In On Cybin</h2>
<div class="lb-trans"><h2>机构投资者对 Cybin 的看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Rathbones Group PLC purchased a new stake in shares of Cybin in the 4th quarter worth about $26,000. Cerity Partners LLC lifted its holdings in Cybin by 488.5% in the 4th quarter. Cerity Partners LLC now owns 88,271 shares of the company's stock valued at $36,000 after purchasing an additional 73,271 shares in the last quarter. Thrive Wealth Management LLC lifted its holdings in Cybin by 141.5% in the 4th quarter. Thrive Wealth Management LLC now owns 128,000 shares of the company's stock valued at $52,000 after purchasing an additional 75,000 shares in the last quarter. Lewis Asset Management LLC purchased a new position in Cybin in the 4th quarter valued at about $116,000. Finally, FNY Investment Advisers LLC lifted its holdings in Cybin by 20,000.0% in the 4th quarter. FNY Investment Advisers LLC now owns 402,000 shares of the company's stock valued at $164,000 after purchasing an additional 400,000 shares in the last quarter. 17.94% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持股进行了调整。Rathbones Group PLC 在第四季度购入了 Cybin 股票，价值约 26,000 美元。 Cerity Partners LLC 在第四季度将其对 Cybin 的持股增加了 488.5%。 Cerity Partners LLC 现在拥有公司股票的 88,271 股，价值 36,000 美元，比上一季度增加了 73,271 股。 Thrive Wealth Management LLC 在第四季度将其对 Cybin 的持股增加了 141.5%。 Thrive Wealth Management LLC 现在拥有公司股票的 128,000 股，价值 52,000 美元，比上一季度增加了 75,000 股。 Lewis Asset Management LLC 在第四季度购入了 Cybin 的新头寸，价值约 116,000 美元。最后，FNY Investment Advisers LLC 在第四季度将其对 Cybin 的持股增加了 20,000.0%。 FNY Investment Advisers LLC 现在拥有公司股票的 402,000 股，价值 164,000 美元，比上一季度增加了 400,000 股。目前，17.94% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>Cybin Stock Performance</h2>
<div class="lb-trans"><h2>Cybin 股票表现</h2>
</div><p>Cybin stock opened at $0.26 on Wednesday. Cybin has a 52 week low of $0.25 and a 52 week high of $0.74. The stock has a market capitalization of $108.84 million, a P/E ratio of -1.26 and a beta of 0.50.</p>
<div class="lb-trans"><p>Cybin 股票周三开盘价为 0.26 美元。 Cybin 股票 52 周最低价为 0.25 美元，52 周最高价为 0.74 美元。该股的市值为 1.0884 亿美元，市盈率为-1.26，β系数为 0.50。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的观点</h2>
</div><p>Separately, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $5.00 price objective on shares of Cybin in a research report on Wednesday, March 13th.</p>
<div class="lb-trans"><p>HC Wainwright 重申对 Cybin 的 “买入” 评级，并在 3 月 13 日的研究报告中给出了 5.00 美元的目标价。</p>
</div><p><strong>View Our Latest Report on CYBN</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 CYBN 的最新报告</strong></p>
</div><h2>Cybin Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Cybin 公司简介（获取免费报告）</h2>
</div><p>Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.</p>
<div class="lb-trans"><p>Cybin Inc 是一家临床阶段的生物制药公司，专注于开发基于致幻物质的治疗药物。该公司的开发管线包括 CYB003，一种氘代哌苷类似物，目前正在进行治疗重度抑郁症和酒精成瘾的 1/2a 期临床试验；CYB004，一种氘代二甲基色胺，目前正在进行治疗广泛性焦虑症的 1 期临床试验；以及 CYB005，一种苯乙胺衍生物，目前处于临床前阶段，用于治疗神经炎症。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Cybin</li>
<li>What is a Special Dividend?</li>
<li>Generac Holdings Stock: Mixed Signals Leave Investors Uncertain</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Analysts and Earnings Propel the S&amp;P 500's Continuous Growth</li>
<li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li>
<li>CrowdStrike Stock Soars, Outpacing Palo Alto in Cybersecurity</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票胜过 Cybin</li>
<li>什么是特别股息？</li>
<li>Generac Holdings 股票：混合信号让投资者感到不确定</li>
<li>投资的股票类型有所不同</li>
<li>分析师和盈利推动标普 500 持续增长</li>
<li>波动时期必须购买的三只沃伦·巴菲特股票</li>
<li>CrowdStrike 股票飙升，超越 Palo Alto 在网络安全领域</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ The Only Retirement Stock You'll Ever Need? Discover Now (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 您唯一需要的退休股票？立即发现（来自市场背后的信息）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjM2" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8636&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cybin right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1,000 美元购买 Cybin 股票？</h2>
</div><p>Before you consider Cybin, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cybin 之前，您需要听到这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶尖分析师悄悄告诉客户现在购买的股票...而 Cybin 不在名单上。</p>
</div><p>While Cybin currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Cybin 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cybin Inc. (NYSEAMERICAN:CYBN) 的空头头寸显著下降